Biogen Drops After Alzheimer's Drug Trial Change Raises Concerns
- Company says it’s adding patients to clarify trial results
- Changes come after Merck stopped trial of late-stage drug
Photographer: Scott Eisen/Bloomberg
This article is for subscribers only.
Biogen Inc. plunged after the company said it was making changes to a trial of an Alzheimer’s disease drug, after a long list of rival drugs failed.
In a presentation to investors Wednesday, Biogen said it would add about 500 more patients to its studies of aducanumab, which is in the final stages of testing and was expected to produce full results later this year. Aducanumab is one the last remaining late-stage Alzheimer’s drugs still in testing.